Wall Street Zen Upgrades Longeveron (NASDAQ:LGVN) to “Hold”

Longeveron (NASDAQ:LGVN) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Longeveron Price Performance

Shares of LGVN opened at $1.10 on Friday. Longeveron has a 52 week low of $0.48 and a 52 week high of $1.83. The stock has a market capitalization of $25.60 million, a price-to-earnings ratio of -0.86 and a beta of -0.18. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.33 and a current ratio of 1.33. The stock has a fifty day moving average of $0.82 and a 200-day moving average of $0.72.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.20. The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.11 million. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%. As a group, sell-side analysts anticipate that Longeveron will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent SEC filing. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.